Douglas W. Bonhaus

4.7k total citations
78 papers, 3.6k citations indexed

About

Douglas W. Bonhaus is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Douglas W. Bonhaus has authored 78 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Cellular and Molecular Neuroscience, 44 papers in Molecular Biology and 15 papers in Organic Chemistry. Recurrent topics in Douglas W. Bonhaus's work include Neuroscience and Neuropharmacology Research (27 papers), Receptor Mechanisms and Signaling (21 papers) and Neurotransmitter Receptor Influence on Behavior (19 papers). Douglas W. Bonhaus is often cited by papers focused on Neuroscience and Neuropharmacology Research (27 papers), Receptor Mechanisms and Signaling (21 papers) and Neurotransmitter Receptor Influence on Behavior (19 papers). Douglas W. Bonhaus collaborates with scholars based in United States, Poland and Switzerland. Douglas W. Bonhaus's co-authors include Richard M. Eglen, James O McNamara, Lyn B. Jakeman, Leon Chang, Robin D. Clark, Erik H.F. Wong, D. L. Price, Edward Leung, Gladys Martin and Z. P. To and has published in prestigious journals such as Journal of Neuroscience, Brain and Scientific Reports.

In The Last Decade

Douglas W. Bonhaus

78 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas W. Bonhaus United States	31	2.2k	1.6k	622	477	335	78	3.6k
Robert J. Naylor United Kingdom	39	2.9k 1.3×	2.0k 1.2×	571 0.9×	518 1.1×	501 1.5×	134	4.9k
Shigeru Okuyama Japan	37	3.2k 1.4×	2.9k 1.8×	722 1.2×	538 1.1×	259 0.8×	148	6.4k
Ewan J. Mylecharane Australia	18	2.5k 1.1×	2.0k 1.2×	866 1.4×	319 0.7×	161 0.5×	39	4.2k
Lee A. Phebus United States	33	1.6k 0.7×	1.0k 0.6×	638 1.0×	734 1.5×	398 1.2×	53	3.6k
P.R. Saxena Netherlands	21	2.4k 1.1×	2.1k 1.3×	1.0k 1.6×	364 0.8×	181 0.5×	53	5.0k
Andrew D. Medhurst United Kingdom	33	1.9k 0.9×	2.0k 1.2×	509 0.8×	559 1.2×	349 1.0×	58	3.9k
Philippe Schoeffter Switzerland	39	2.0k 0.9×	2.1k 1.3×	891 1.4×	233 0.5×	171 0.5×	80	3.9k
Malcolm J. Sheardown Denmark	32	2.8k 1.3×	2.6k 1.6×	414 0.7×	300 0.6×	299 0.9×	82	4.1k
Xavier Langlois Belgium	38	2.3k 1.1×	2.1k 1.3×	510 0.8×	435 0.9×	223 0.7×	104	4.2k
Tony Priestley United States	23	2.6k 1.2×	2.3k 1.4×	492 0.8×	218 0.5×	153 0.5×	50	3.8k

Countries citing papers authored by Douglas W. Bonhaus

Since Specialization

Citations

This map shows the geographic impact of Douglas W. Bonhaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas W. Bonhaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas W. Bonhaus more than expected).

Fields of papers citing papers by Douglas W. Bonhaus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas W. Bonhaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas W. Bonhaus. The network helps show where Douglas W. Bonhaus may publish in the future.

Co-authorship network of co-authors of Douglas W. Bonhaus

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas W. Bonhaus. A scholar is included among the top collaborators of Douglas W. Bonhaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas W. Bonhaus. Douglas W. Bonhaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Price, D. L., Asma Khan, Rachel Angers, et al.. (2023). In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease. npj Parkinson s Disease. 9(1). 114–114. 16 indexed citations

Price, D. L., Maya A. Koike, Asma Khan, et al.. (2018). The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease. Scientific Reports. 8(1). 16165–16165. 117 indexed citations

Price, D. L., Edward Rockenstein, Michael Mante, et al.. (2016). Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies. Scientific Reports. 6(1). 29523–29523. 42 indexed citations

Masliah, Eliezer, Edward Rockenstein, D. L. Price, et al.. (2014). Small molecules targeting the formation of neurotoxic oligomers for the treatment of AD/PD: a second look. Neurobiology of Aging. 35. S15–S15. 1 indexed citations

Price, D. L., Douglas W. Bonhaus, & Krista McFarland. (2012). Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease. Behavioural Pharmacology. 23(4). 426–433. 27 indexed citations

Gardell, Luis R., Kimberly E. Vanover, Robert W. Johnson, et al.. (2007). ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models. Journal of Pharmacology and Experimental Therapeutics. 322(2). 862–870. 47 indexed citations

Martin, Renée S., Paul Reynen, Thomas K. H. Chang, et al.. (2002). Pharmacological Comparison of a Recombinant CB1 Cannabinoid Receptor with Its Ga16 Fusion Product. SLAS DISCOVERY. 7(3). 281–289. 6 indexed citations

Bonhaus, Douglas W., Lee A. Flippin, Robert Greenhouse, et al.. (1999). RS‐127445: a selective, high affinity, orally bioavailable 5‐HT_2B receptor antagonist. British Journal of Pharmacology. 127(5). 1075–1082. 95 indexed citations

Bonhaus, Douglas W., et al.. (1998). Absorption and Brain Penetration of a High Affinity, Highly Selective 5‐HT_2C Receptor Antagonist, RS‐102221. Annals of the New York Academy of Sciences. 861(1). 269–269. 7 indexed citations

10.

Terry, Alvin V., Jerry J. Buccafusco, William James Jackson, et al.. (1998). Enhanced delayed matching performance in younger and older macaques administered the 5-HT 4 receptor agonist, RS 17017. Psychopharmacology. 135(4). 407–415. 61 indexed citations

11.

Jasper, Jeffrey R., John Lesnick, Leon Chang, et al.. (1998). Ligand Efficacy and Potency at Recombinant α2 Adrenergic Receptors. Biochemical Pharmacology. 55(7). 1035–1043. 144 indexed citations

12.

Bonhaus, Douglas W., Joel G. Berger, Nika Adham, et al.. (1997). [ 3 H]RS 57639, a High Affinity, Selective 5-HT 4 Receptor Partial Agonist, Specifically Labels Guinea-pig Striatal and Rat Cloned (5-HT 4S and 5-HT 4L ) Receptors. Neuropharmacology. 36(4-5). 671–679. 8 indexed citations

13.

Bonhaus, Douglas W., Ronald C. Herman, Z. Cao, et al.. (1996). The β1 Sodium Channel Subunit Modifies the Interactions of Neurotoxins and Local Anesthetics with the Rat Brain IIA α Sodium Channel in Isolated Membranes but not in Intact Cells. Neuropharmacology. 35(5). 605–613. 12 indexed citations

14.

Wong, Erik H.F., et al.. (1995). Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders. Behavioural Brain Research. 73(1-2). 249–252. 60 indexed citations

15.

To, Z. P., Douglas W. Bonhaus, Richard M. Eglen, & Lyn B. Jakeman. (1995). Characterization and distribution of putative 5‐ht₇receptors in guinea‐pig brain. British Journal of Pharmacology. 115(1). 107–116. 190 indexed citations

16.

Eglen, Richard M., Douglas W. Bonhaus, Robin D. Clark, et al.. (1994). (R) and (S) RS 56532: Mixed 5-HT3 and 5-HT4 receptor ligands with opposing enantiomeric selectivity. Neuropharmacology. 33(3-4). 515–526. 16 indexed citations

17.

Clark, Robin D., Aaron B. Miller, Jacob Berger, et al.. (1993). 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists. Journal of Medicinal Chemistry. 36(18). 2645–2657. 85 indexed citations

18.

Bonhaus, Douglas W. & James O McNamara. (1992). Uncompetitive antagonist binding: a biochemical index of activation of the NMDA receptor-coupled ion channel. Elsevier eBooks. 8. 181–188. 4 indexed citations

19.

Bonhaus, Douglas W., et al.. (1991). Activation of substantia nigra pars reticulata neurons: role in the initiation and behavioral expression of kindled seizures. Brain Research. 545(1-2). 41–48. 32 indexed citations

20.

Bonhaus, Douglas W., H. Pasantes‐Morales, & Ryan J. Huxtable. (1985). Actions of guanidinoethane sulfonate on taurine concentration, retinal morphology and seizure threshold in the neonatal rat. Neurochemistry International. 7(2). 263–270. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact